Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.

NCT00169533 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00169533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00169533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
August 19, 2004
Completion date
May 5, 2009
Enrollment
31 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast